76 terminated. 76 Phase 1, 33 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 76 | Terminated 76 |
| Phase 2 | 33 | Terminated 33 |
Follow Anemia: new trials by email Literature Review of Anemia trials Research Report on Anemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease Pociredir - Sickle Cell Disease | Phase 1 | Terminated | Fulcrum Therapeutics | 13 | 2025-12-13 | 2026-06-18 |
| CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy ThisCART19A - Autoimmune Hemolytic Anemia, CD19 CAR-T Cell Infusion | Phase 1 | Terminated | Institute of Hematology & Blood Diseases Hospital, China | 1 | 2024-01-20 | 2026-11-04 |
| Siplizumab for Sickle Cell Disease Transplant Siplizumab, Exchange Transfusion, Total Body Irradiation - Anemia, Sickle Cell | Phase 1 / Phase 2 | Terminated | Columbia University | 1 | 2023-09-28 | 2026-06-10 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years GSK4172239D, Placebo - Hematologic Diseases, Anaemia, Sickle Cell | Phase 1 | Terminated | GlaxoSmithKline | 11 | 2023-08-26 | 2026-01-22 |
| Study of GBT021601 in Participants With Renal Impairment GBT021601 - Renal Impairment | Phase 1 | Terminated | Pfizer | 8 | 2023-06-29 | 2024-10-15 |
| PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy Linperlisib - Autoimmune Hemolytic Anemia, Failure of Two Rounds of Treatment | Phase 1 | Terminated | Institute of Hematology & Blood Diseases Hospital, China | 4 | 2023-01-13 | 2026-02-11 |
| AB1 in Adult Patients With Sickle Cell Disease (SCD) AB1 - Sickle Cell Disease | Phase 1 / Phase 2 | Terminated | Nirmish Shah | 16 | 2022-12-05 | 2026-10-15 |
| Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB) MGTA-117 - Acute Myeloid Leukemia, Myelodysplasia | Phase 1 | Terminated | Magenta Therapeutics, Inc. | 22 | 2022-02-14 | 2023-02-09 |
| To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma INCB000928 - Myelodysplastic Syndromes, Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 22 | 2021-08-19 | 2025-10-22 |
| A Safety and Efficacy Study Evaluating ET-01 in Subjects with Transfusion Dependent Β-Thalassaemia ET-01 - Transfusion Dependent Beta-Thalassaemia | Phase 1 | Terminated | EdiGene (GuangZhou) Inc. | 8 | 2021-08-17 | 2025-03-30 |
| Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088 SAR445088 - Autoimmune Haemolytic Anaemia | Phase 1 | Terminated | Bioverativ, a Sanofi company | 9 | 2021-03-22 | 2025-09-11 |
| A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease Voxelotor - Sickle Cell Disease, Sickle Cell Nephropathy | Phase 1 / Phase 2 | Terminated | University of Illinois at Chicago | 12 | 2021-03-16 | 2025-04-03 |
| REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy REGN7257 - Severe Aplastic Anemia (SAA) | Phase 1 | Terminated | Regeneron Pharmaceuticals | 17 | 2021-01-13 | 2026-06-22 |
| A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS TP-0184 - Anemia in Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | Sumitomo Pharma America, Inc. | 2 | 2020-12-28 | 2023-11-09 |
| Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD) OTQ923 - Sickle Cell Disease | Phase 1 | Terminated | Novartis Pharmaceuticals | 4 | 2020-08-25 | 2026-01-08 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Imatinib for Pain in Sickle Cell Anemia Imatinib Mesylate - Sickle Cell Disease | Phase 1 / Phase 2 | Terminated | Indiana University | 7 | 2020-02-26 | 2026-01-29 |
| CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734 - Anemia, Sickle Cell | Phase 1 | Terminated | CSL Behring | 1 | 2019-10-02 | 2021-06-18 |
| The Use of Trifluoperazine in Transfusion Dependent DBA Trifluoperazine - Diamond Blackfan Anemia, Pure Red Cell Aplasia | Phase 1 / Phase 2 | Terminated | Adrianna Vlachos, MD | 2 | 2019-09-13 | 2022-12-14 |
| Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients Iron Sucrose - Epithelial Ovarian Cancer, Anemia | Phase 1 / Phase 2 | Terminated | University of Wisconsin, Madison | 9 | 2019-07-29 | 2023-01-05 |
Showing 20 of 76. Sign in to see all of them.
Anemia, Sickle Cell (25) · Anemia, Refractory, with Excess of Blasts (16) · Myelodysplastic Syndromes (14) · Leukemia, Myeloid, Acute (13) · Leukemia (10) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (10) · Lymphoma, Non-Hodgkin (9) · Fanconi Anemia (8) · Anemia, Aplastic (7) · Hodgkin Disease (7) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Multiple Myeloma (6) · Thalassemia (6) · Anemia, Diamond-Blackfan (5)
Hemic and Lymphatic Diseases (76) · Hematologic Diseases (72) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (37) · Bone Marrow Diseases (35) · Genetic Diseases, Inborn (35) · Anemia, Hemolytic (33) · Anemia, Hemolytic, Congenital (28) · Hemoglobinopathies (23) · Pathological Conditions, Signs and Symptoms (23) · Neoplasms (22) · Neoplasms by Histologic Type (22) · Pathologic Processes (21) · Immune System Diseases (20) · Disease Attributes (19)
Cyclophosphamide (7) · Whole-Body Irradiation (7) · Mycophenolic Acid (5) · fludarabine phosphate (5) · Alemtuzumab (4) · Sirolimus (4) · fludarabine (4) · Cord Blood Stem Cell Transplantation (3) · AP 1903 reagent (2) · Antilymphocyte Serum (2) · Arsenic Trioxide (2) · Bortezomib (2) · Busulfan (2) · Cyclosporine (2) · Filgrastim (2)
Incyte Corporation (4) · Bellicum Pharmaceuticals (3) · Fred Hutchinson Cancer Center (3) · Masonic Cancer Center, University of Minnesota (3) · Baylor College of Medicine (2) · Columbia University (2) · GlaxoSmithKline (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Washington University School of Medicine (2) · Adrianna Vlachos, MD (1) · Agios Pharmaceuticals, Inc. (1) · Alexion Pharmaceuticals, Inc. (1) · Amgen (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Beth Israel Deaconess Medical Center (1)
United States (63) · Italy (6) · France (5) · United Kingdom (5) · China (3) · Canada (2) · Bulgaria (1) · Czechia (1) · Germany (1) · Lebanon (1) · Netherlands (1) · Norway (1) · Poland (1) · Romania (1) · South Korea (1)
Adrianna Vlachos, MD (2) · Allistair Abraham, MD (1) · Andre Dejam, MD, PhD (1) · Ann Woolfrey (1) · Anthony Stein (1) · Bill Lundberg, MD (1) · Claudio G. Brunstein, MD, PhD (1) · Colin A Sieff, MB.BCh (1) · Doron Schwartz, Professor (1) · Ekatarine Asatiani, MD (1)
PMID 18550886, PMID 19139736, PMID 19840322, PMID 20117846, PMID 20644039, PMID 20732454, PMID 20797926, PMID 20936416, PMID 23973010, PMID 25824692, PMID 27862048, PMID 36123234, PMID 36860093, PMID 36975201, PMID 37254256, PMID 37646679, PMID 37939122, PMID 38866240, PMID 39863139, PMID 39891377, PMID 40308078, PMID 40419809, PMID 41225660, PMID 41984996
2023 (2), 2014 (1), 2015 (1), 2017 (1), 2019 (1), P01CA044991 (1), P01CA049605 (1), P20GM109021 (1), P30CA072720 (1)